Non Serious Adverse Drug Reactions Report

Start Date:2016-06-20 End Date:2016-06-21

Study :EMR200136_583	Investigator :NA		Country of Investigator :Romania	SiteNo:007		
Subject No :007-0007	Subject Initials :	DOB :08/01/1981	Sex:Female	Race:Caucasian	Height:163(cm)	Weight:60(kg)
First administration date of batch :			Batch number :			

Study Drug	Start Date	Dose	Change in Dose
Visit 2 (Month 3)	06/05/2015	9	
Visit 5 (Month12)/Early Termination			
Visit 3 (Month 6)	06/05/2015	9	
Visit 1/ Baseline (Day 1)	06/05/2015	9	
Visit 4 (Month 9)	06/05/2016	9	

Adverse Event	Start Date	End Date	Time related to study treatment	Causality to study drug	Severity
hypothyroidism	12/16/2015			Suspected	Mild

Causality Factors	Action Taken with Study Treatment	Other action taken	Outcome	AE Special Interest	AE dose limiting toxicity
Other(Othervalue:Rebif therapy)	Dose not changed	Concomitant medication	Ongoing		

Event description:

Subject received concomitant medications:Yes

Name of medication	Start Date	Ongoing	End Date	Dose	Unit	Frequency
Stilnox	06/02/2015	Yes		1	tb	QD
Alanerv	06/06/2015		11/30/2015	2	tb	BID
Acetaminophen	06/05/2015	Yes		500	mg	PRN
L-Thyroxin	Uk-Jan-2016	Yes		25	mcg	QD

Does the subject have any relevant past or present medical conditions:Yes

Condition	Start Date	Related to study condition	Ongoing
Depression			Yes

Non Serious Adverse Drug Reactions Report

Start Date:2016-06-20 End Date:2016-06-21

Study :EMR200136_583	Investigator :NA		Country of Investigator :Romania	SiteNo:007		
Subject No :007-0010	Subject Initials :	DOB :03/25/1989	Sex:Male	Race:Caucasian	Height:179(cm)	Weight:63(kg)
First administration date of batch :			Batch number :			

Study Drug	Start Date	Dose	Change in Dose
Visit 2 (Month 3)	06/08/2015	9	
Visit 5 (Month12)/Early Termination			
Visit 3 (Month 6)	06/08/2015	9	
Visit 1/ Baseline (Day 1)	06/08/2015	9	
Visit 4 (Month 9)	06/08/2015	9	

Adverse Event	Start Date	End Date	Time related to study treatment	Causality to study drug	Severity
elevated ALT and AST	09/04/2015			Suspected	Moderate

Causality Factors	Action Taken with Study Treatment	Other action taken	Outcome	AE Special Interest	AE dose limiting toxicity
None(Othervalue:)		Concomitant medication	Ongoing		

Event description:

Subject received concomitant medications:Yes

Name of medication	Start Date	Ongoing	End Date	Dose	Unit	Frequency
LIV52	09/04/2015		01/26/2016	6	tb	TID
Acetaminophen	06/08/2015		06/08/2015	500	mg	PRN
Solu-Medrol	01/27/2016		01/29/2016	1000	mg	QD
LIV 52	01/27/2016		02/22/2016	3	tb	TID
Controloc	01/27/2016		02/03/2016	20	mg	QD
Rivotril 0.5mg	01/27/2016	Yes		500	mcg	BID
Milgamma	01/30/2016		02/08/2016	3	tb	TID

Does the subject have any relevant past or present medical conditions:No

Condition	Start Date	Related to study condition	Ongoing